Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Recall request rebuffed

This article was originally published in The Tan Sheet

Executive Summary

FDA warns consumers that Westco Fruit and Nuts Inc.'s peanuts and peanut-derived products could be contaminated with salmonella. FDA said March 23 it formally asked the Irvington, N.J.-based company to recall products that may contain ingredients sourced by from the Peanut Corporation of America (1"The Tan Sheet" March 23, 2009, p. 5). A spokeswoman said FDA hopes Westco will recall the products, and is "considering additional enforcement actions against the company if it doesn't cooperate." Westco declined to comment

You may also be interested in...

Congress Stresses Food Safety Responsibility For All Links In Supply Chain

Food and dietary supplement distributors and retailers should share responsibility with ingredient suppliers for preventing contamination outbreaks, according to House Energy and Commerce Committee members

QUOTED. 28 February 2020. Jubilee Brown.

Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.

Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts